Literature DB >> 16106210

Developing practice guidelines for the administration of intravenous immunoglobulin.

Elyse Murphy1, Sarah Martin, Jardiolyn Valino Patterson.   

Abstract

As the use of intravenous immunoglobulin (IGIV) continues to expand, infusion nurses have a greater need for a comprehensive understanding of the product, patient risk factors, and comorbidities when developing guidelines for administering IGIV. Because immunoglobulin therapy is a blood derivative product, many nurses may not have as much experience administering this type of infusion. This article provides an in-depth overview of immunoglobulin therapy and helps to define the infusion nurse's major role in coordinating, assessing, and ensuring patient safety during IGIV administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16106210     DOI: 10.1097/00129804-200507000-00009

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  6 in total

1.  Immune globulin subcutaneous (human), 20% liquid.

Authors: 
Journal:  P T       Date:  2010-08

2.  Immune globulin subcutaneous (human) vivaglobin: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

3.  An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

4.  Drug-induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis.

Authors:  Kevin Bihan; Nicolas Weiss; Hélène Théophile; Christian Funck-Brentano; Bénédicte Lebrun-Vignes
Journal:  Br J Clin Pharmacol       Date:  2019-08-01       Impact factor: 4.335

5.  Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates.

Authors:  John W Sleasman; Carla M Duff; Theresa Dunaway; Mikhail A Rojavin; Mark R Stein
Journal:  J Clin Immunol       Date:  2010-03-10       Impact factor: 8.317

6.  Treatment of multiple system atrophy using intravenous immunoglobulin.

Authors:  Peter Novak; Arlene Williams; Paula Ravin; Omar Zurkiya; Amir Abduljalil; Vera Novak
Journal:  BMC Neurol       Date:  2012-11-01       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.